Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates

Blood

Volumn 109, Issue 9, 2007, Pages 3733-3740

  Gruber, András ^a   Marzec, Ulla M ^a   Bush, Leslie ^b   Di Cera, Enrico ^b   Fernández, José A ^c   Berny, Michelle A ^a   Tucker, Erik I ^a   McCarty, Owen J T ^a   Griffin, John H ^c   Hanson, Stephen R ^a  

^a Oregon Health and Science University Department of Biomedical Engineering   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ENOXAPARIN; HEMOSTATIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DRUG ACTIVITY; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE; THROMBOSIS;

EID: 34247379463     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-07-035147     Document Type: Article

References (55)

1. Anderson RN, Smith BL. Deaths: leading causes for 2002. National Vital Statistics Report. 2005;53:1-90.
2. Comp PC, Jacocks RM, Ferrell GL, Esmon CT. Activation of protein C in vivo. J Clin Invest. 1982;70:127-134.
3. Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C. J Clin Invest. 1993;92:2003-2012.
4. Wu QY, Sheehan JP, Tsiang M, Lentz SR, Birktoft JJ, Sadler JE. Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin- binding activities of human thrombin. Proc Natl Acad Sci U S A. 1991;88:6775-6779.
5. Gruber A, Cantwell AM, Di Cera E, Hanson SR. The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. J Biol Chem. 2002;277:27581-27584.
6. Gibbs CS, Coutre SE, Tsiang M, et al. Conversion of thrombin into an anticoagulant by protein engineering. Nature. 1995;378:413-416.
7. Tsiang M, Jain AK, Dunn KE, Rojas ME, Leung LLK, Gibbs CS. Functional mapping of the surface residues of human thrombin. J Biol Chem. 1995;270:16854-16863.
8. Tsiang M., Paborsky LR, Li WX, et al. Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo. Biochemistry. 1996;35:16449-16457.
9. Cantwell AM, Di Cera E. Rational design of a potent anticoagulant thrombin. J Biol Chem. 2000;275:39827-39830.
10. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem. 1994;269:26486-26491.
11. Laszik Z, Mitro A, Taylor FB, Ferrell G, Esmon CT. Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation. 1997;96:3633-3640.
12. Ye X, Fukudome K, Tsuneyoshi N, et al. The endothelial cell protein C receptor (EPCR) functions as a primary receptor for protein C activation on endothelial cells in arteries, veins, and capillaries. Biochem Biophys Res Commun. 1999;259:671-677.
13. Taylor FB, Peer GT, Lockhart MS, Ferrell G, Esmon CT. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood. 2001;97:1685-1688.
14. Castellino FJ, Liang Z, Volkir SP, et al. Mice with a severe deficiency of the endothelial protein C receptor gene develop, survive, and reproduce normally, and do not present with enhanced arterial thrombosis after challenge. Thromb Haemost. 2002;88:462-472.
15. Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res. 2004;114:321-327.
16. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol. 1999;84:1391-1395.
17. Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol. 2002;40:1943-1950.
18. Chen WH, Lau CP, Lau YK, et al. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invasive Cardiol. 2002;14:439-442.
19. Carnendran L, Borkowski R, Markabawi B, Warner MF. Safety and efficacy of low-dose intravenous enoxaparin and GP IIb/IIIa inhibitor therapy during PCI. J Invasive Cardiol. 2003;15:235-238.
20. Martin JL, Fry ET, Sanderink GJ, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv. 2004;61:163-170.
21. Gruber A, Fernandez JA, Bush L, et al. Limited generation of activated protein C during infusion of the protein C activator thrombin analog W215A/E217A in primates. J Thromb Haemost. 2006;4:392-397.
22. Smith PS, Baglini R, Meissner GF. The prolonged bleeding time in hemophilia A: comparison of two measuring techniques and clinical associations. Am J Clin Pathol. 1985;83:211-215.
23. Stuart MJ, Walenga RW, Sadowitz PD, Maltby A, Kelton JG, Gauldie J. Bleeding time in hemophilia A: potential mechanisms for prolongation. J Pediatr. 1986;108:215-218.
24. Kutti J, Safai-Kutti S, Sigvaldason A, Edgar B, Lundborg P. The effect of acetylsalicylic acid in 3 different formulations on in vitro and in vivo platelet function tests: an experimental study on healthy male volunteers. Scand J Haematol. 1984;32:379-384.
25. Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood. 1992;79:2340-2348.
26. Geiger M, White TM, Griffin JH. Functional assays for protein C activity and protein C inhibitor activity in plasma. Thromb Haemost. 1989;61:86-92.
27. McCarty OJ, Tien N, Bochner BS, Konstantopoulos K. Exogenous eosinophil activation converts PSGL-1-dependent binding to CD18-dependent stable adhesion to platelets in shear flow. Am J Physiol Cell Physiol. 2003;284:C1223-C1234.
28. McCarty OJ, Larson MK, Auger JM, et al. Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow. J Biol Chem. 2005;280:39474-39484.
29. Cohen M, Theroux P, Weber S, et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol. 1999;71:273-281.
30. Sarich TC, Wolzt M, Eriksson UG, et al. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin, and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J Am Coll Cardiol. 2003;41:557-564.
31. Bang CJ, Riedel B, Talstad I, Berstad A. Haemorrhagic effect of enoxaparin, a low molecular weight heparin: comparison with unfractionated heparin in humans. Scand J Gastroenterol. 1992;27:924-928.
32. Matthiasson SE, Lindblad B, Stjernquist U, Bergqvist D. The haemorrhagic effect of low molecular weight heparins, dermatan sulphate and hirudin. Haemostasis. 1995;25:203-211.
33. Doutremepuich C, Azougagh Oualane F, Doutremepuich F, Fareed J. New class of heparin derivatives with a potent antithrombotic effect and a very limited hemorrhagic activity. Thromb Res. 1996;83:217-228.
34. Gikakis N, Rao AK, Miyamoto S, et al. Enoxaparin suppresses thrombin formation and activity during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg. 1998;116:1043-1051.
35. Schenk JF, Glusa E, Radziwon P, Butti A, Markwardt F, Breddin HK. A recombinant hirudin (IKHIR02) in healthy volunteers, I: effects on coagulation parameters and bleeding time. Haemostasis. 1996;26:140-149.
36. Bradbrook ID, Magnani HN, Moelker HC, et al. ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol. 1987;23:667-675.
37. Melandri G, Semprini F, Cervi V, et al. Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris: a double-blind, randomized, placebo-controlled trial. Circulation. 1993;88:2517-2523.
38. Greer IA, Gibson JL, Young A, Johnstone J, Walker ID. Effect of ketorolac and low-molecular-weight heparin individually and in combination on haemostasis. Blood Coagul Fibrinolysis. 1999;10:367-373.
39. Abraham E, Laterre PF, Garg R, et al. Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group: drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353:1332-1341.
40. Castelli EE, Culley CM, Fink MP. Challenge and rechallenge: drotrecogin alfa (activated)-induced prolongation of activated partial thromboplastin time in a patient with severe sepsis. Pharmacotherapy. 2005;25:1147-1150.
41. Barton P, Kalil AC, Nadel S, et al. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics. 2004;113:7-17.
42. Gruber A, Griffin JH, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood. 1989;73:639-642.
43. Heeb MJ, Gruber A, Griffin JH. Identification of divalent metal ion-dependent inhibition of activated protein C by alpha 2-macroglobulin and alpha 2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin, and plasmin. J Biol Chem. 1991;266:17606-17612.
44. Liaw PC, Mather T, Oganesyan N, Ferrell GL, Esmon CT. Identification of the protein C/activated protein C binding sites on the endothelial cell protein C receptor: implications for a novel mode of ligand recognition by a major histocompatibility complex class 1-type receptor. J Biol Chem. 2001;276:8364-8370.
45. Perez-Casal M, Downey C, Fukudome K, Marx G, Toh CH. Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood. 2005;105:1515-1522.
46. Suzuki K, Nishioka J, Hayashi T, Kosaka Y. Functionally active thrombomodulin is present in human platelets. J Biochem (Tokyo). 1988;104:628-632.
47. Grey ST, Hancock WW. A physiologic anti-inflammatory pathway based on thrombomodulin expression and generation of activated protein C by human mononuclear phagocytes. J Immunol. 1996;156:2256-2263.
48. Hagberg IA, Roald HE, Lyberg T. Adhesion of leukocytes to growing arterial thrombi. Thromb Haemost. 1998;80:852-858.
49. Feistritzer C, Sturn DH, Kaneider NC, Djanani A, Wiedermann CJ. Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. J Allergy Clin Immunol. 2003;112:375-381.
50. Sturn DH, Kaneider NC, Feistritzer C, Djanani A, Fukudome K, Wiedermann CJ. Expression and function of the endothelial protein C receptor in human neutrophils. Blood. 2003;102:1499-1505.
51. Conway EM, Nowakowski B, Steiner-Mosonyi M. Human neutrophils synthesize thrombomodulin that does not promote thrombin-dependent protein C activation. Blood. 1992;80:1254-1263.
52. Palabrica T, Lobb R, Furie BC, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature. 1992;359:848-851.
53. McGuinness CL, Humphries J, Waltham M, Burnand KG, Collins M, Smith A. Recruitment of labeled monocytes by experimental venous thrombi. Thromb Haemost. 2001;85:1018-1024.
54. Merhi Y, Provost P, Guidoin R, Latour JG. Importance of platelets in neutrophil adhesion and vasoconstriction after deep carotid arterial injury by angioplasty in pigs. Arterioscler Thromb Vasc Biol. 1997;17:1185-1191.
55. Glaser CB, Morser J, Clarke JH, et al. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity: a potential rapid mechanism for modulation of coagulation. J Clin Invest. 1992;90:2565-2573.